Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Doff Portland Limited holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This 1 action represents the total volume of the company's active engagement with the patent office at this time. Because the portfolio is focused on biotechnology and pharmaceuticals, the legal strategy must account for the specific examination standards of these sectors.
The current workload is distributed across 1 distinct examiner and 1 distinct art unit. This distribution indicates that the company's pending intellectual property is being evaluated by 1 segment of the patent office. For a practitioner, this means that the outcome of the 1 pending office action depends on the feedback from 1 technical division. There is no variation of examiner perspectives across the current pending filings.
NGUYEN, JOHN P is identified as the busiest examiner for this portfolio. This individual is currently responsible for 1 pending office action. Since the total number of pending actions is also 1, NGUYEN, JOHN P manages the entirety of the company's active prosecution. This level of concentration requires a focused approach to communication with this specific examiner to resolve the outstanding action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, JOHN P | 1 | 43.9% | +41.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18174006 | Mollusc Barrier | NGUYEN, JOHN P | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18174006 | Mollusc Barrier | NGUYEN, JOHN P | 1619 | §103 | Non-Final OA | — | Pending | Feb 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDoff Portland Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
John P Nguyen has the most, with 1 of Doff Portland Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
